Spero Therapeutics, Inc.
SPRO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -74.2% | 100.9% | -61% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 100% | 100% | -131.6% | -529% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -242.2% | -20% | -247.8% | -138.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -242.2% | -14.4% | -236.1% | -138.8% |
| EPS Diluted | -0.13 | -0.03 | -0.25 | -0.39 |
| % Growth | -329% | 87.9% | 35.9% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |